MX2017008186A - Anticuerpos humanos para la hemaglutinina de influenza. - Google Patents

Anticuerpos humanos para la hemaglutinina de influenza.

Info

Publication number
MX2017008186A
MX2017008186A MX2017008186A MX2017008186A MX2017008186A MX 2017008186 A MX2017008186 A MX 2017008186A MX 2017008186 A MX2017008186 A MX 2017008186A MX 2017008186 A MX2017008186 A MX 2017008186A MX 2017008186 A MX2017008186 A MX 2017008186A
Authority
MX
Mexico
Prior art keywords
antibodies
influenza
human antibodies
bind
influenza hemagglutinin
Prior art date
Application number
MX2017008186A
Other languages
English (en)
Other versions
MX386403B (es
Inventor
Viau Jonathan
Olson William
A Purcell Lisa
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2017008186A publication Critical patent/MX2017008186A/es
Publication of MX386403B publication Critical patent/MX386403B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona anticuerpos monoclonales, o fragmentos de unión a antígeno de los mismos, que se unen a la proteína hemaglutinina de influenza (HA), composiciones farmacéuticas que comprenden los anticuerpos y métodos de uso. Los anticuerpos de la invención son útiles para inhibir o neutralizar la actividad del virus de la influenza, proporcionando así un medio para tratar o prevenir la infección por influenza en humanos. En algunas modalidades, la invención proporciona el uso de uno o más anticuerpos que se unen a la HA de influenza para prevenir la unión y/o entrada viral en las células huésped. Los anticuerpos de la invención pueden usarse profilácticamente o terapéuticamente y pueden usarse solos o en combinación con uno o más agentes antivirales o vacunas.
MX2017008186A 2014-12-19 2015-12-18 Anticuerpos humanos para hemaglutinina de influenza. MX386403B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094752P 2014-12-19 2014-12-19
US201562152122P 2015-04-24 2015-04-24
PCT/US2015/066654 WO2016100807A2 (en) 2014-12-19 2015-12-18 Human antibodies to influenza hemagglutinin

Publications (2)

Publication Number Publication Date
MX2017008186A true MX2017008186A (es) 2018-02-09
MX386403B MX386403B (es) 2025-03-04

Family

ID=55073153

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017008186A MX386403B (es) 2014-12-19 2015-12-18 Anticuerpos humanos para hemaglutinina de influenza.
MX2021007679A MX2021007679A (es) 2014-12-19 2017-06-19 Anticuerpos humanos para hemaglutinina de influenza.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007679A MX2021007679A (es) 2014-12-19 2017-06-19 Anticuerpos humanos para hemaglutinina de influenza.

Country Status (19)

Country Link
US (3) US10392432B2 (es)
EP (1) EP3233908A2 (es)
JP (2) JP6711828B2 (es)
KR (1) KR102729973B1 (es)
CN (1) CN108064240B (es)
AU (1) AU2015364415B2 (es)
BR (1) BR112017012944A2 (es)
CA (1) CA2969749A1 (es)
CL (2) CL2017001610A1 (es)
CO (1) CO2017006580A2 (es)
EA (1) EA036953B1 (es)
IL (1) IL252659B (es)
MX (2) MX386403B (es)
MY (1) MY185320A (es)
PH (1) PH12017500949A1 (es)
SG (2) SG10202010170SA (es)
TW (2) TWI702229B (es)
UY (1) UY36458A (es)
WO (1) WO2016100807A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3419663A1 (en) 2016-02-24 2019-01-02 Visterra, Inc. Formulations of antibody molecules to influenza virus
US11242400B2 (en) * 2016-09-21 2022-02-08 Aptevo Research And Development Llc CD123 binding proteins and related compositions and methods
WO2018075621A1 (en) * 2016-10-19 2018-04-26 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor
TWI781130B (zh) * 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2019006162A1 (en) 2017-06-28 2019-01-03 Bluefin Biomedicine, Inc. ANTI-LY6H ANTIBODIES AND CONJUGATES ANTIBODY-MEDICINE
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
SMT202100307T1 (it) 2018-01-26 2021-07-12 Regeneron Pharma Anticorpi e frammenti di legame di anti-tmprss2
SG11202006379UA (en) * 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
WO2019169231A1 (en) 2018-03-02 2019-09-06 The University Of Chicago Methods and composition for neutralization of influenza
KR20200060969A (ko) * 2018-11-23 2020-06-02 (주)셀트리온 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법
US12459991B2 (en) 2019-02-12 2025-11-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
CN113924147A (zh) * 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
AU2020256225B9 (en) * 2019-04-03 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
WO2020243572A2 (en) 2019-05-31 2020-12-03 Washington University Pan-neuraminidase inhibiting antibodies
US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections
WO2021026064A2 (en) * 2019-08-06 2021-02-11 Regents Of The University Of Minnesota Compositions and methods for treating serpin b13 disorders
BR112022007923A2 (pt) * 2019-10-28 2022-07-26 Regeneron Pharma Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza
IL294989A (en) * 2020-01-24 2022-09-01 Regeneron Pharma Conjugated protein-antiviral compounds
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP7772702B2 (ja) 2020-02-10 2025-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｔｍｐｒｓｓ２抗体および抗原結合断片
DK4045533T5 (da) 2020-03-26 2024-07-29 Univ Vanderbilt Humane monoklonale antistoffer mod svær akut respiratorisk syndrom-coronavirus 2 (sars-cov-2)
US20230122364A1 (en) * 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
CN113527483B (zh) * 2020-04-17 2023-09-22 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
EP4142739A2 (en) 2020-04-27 2023-03-08 Twist Bioscience Corporation Variant nucleic acid libraries for coronavirus
US20230391856A1 (en) * 2020-10-23 2023-12-07 Icahn School Of Medicine At Mount Sinai Sars-cov-2 antibodies and uses thereof
KR20230135569A (ko) * 2020-11-23 2023-09-25 비르 바이오테크놀로지, 인코포레이티드 인플루엔자 a 바이러스에 대한 항체
KR102604669B1 (ko) * 2021-03-30 2023-11-21 충남대학교산학협력단 조류인플루엔자 바이러스의 ha 단백질에 특이적인 단클론항체, 및 이의 용도
CA3220081A1 (en) 2021-07-28 2023-02-02 Thomas Nittoli Protein-antiviral compound conjugates
CN118234750A (zh) * 2021-09-02 2024-06-21 纪念斯隆-凯特琳癌症中心 抗cd33抗体和其用途
WO2023122647A2 (en) * 2021-12-22 2023-06-29 The University Of Chicago Methods for detecting or treating influenza infections
AU2023208050A1 (en) 2022-01-14 2024-07-04 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof
EP4626553A2 (en) 2022-11-30 2025-10-08 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
CN115993452B (zh) * 2023-03-23 2023-06-16 深圳市卫光生物制品股份有限公司 一种流感病毒疫苗血凝素含量测定方法及试剂盒
WO2025077869A1 (en) * 2023-10-13 2025-04-17 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ny-eso-1 antibodies and uses thereof
WO2025117727A1 (en) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
TW202540428A (zh) 2024-01-26 2025-10-16 美商雷傑納榮製藥公司 使用漿細胞耗乏劑及／或ｂ細胞耗乏劑遏制宿主抗ａａｖ抗體反應且實現ａａｖ轉導及重複給藥的方法及組成物
WO2025166216A1 (en) * 2024-02-02 2025-08-07 The Board Of Regents Of The University Of Texas System Trop2-targeting antibodies and uses thereof
WO2025184137A1 (en) * 2024-02-27 2025-09-04 Adimab, Llc Influenza antibodies and methods of use thereof
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025255258A2 (en) * 2024-06-05 2025-12-11 Vaxart, Inc. Antibodies targeting gii genotypes of human norovirus

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CN102046654A (zh) 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
CA2687147C (en) 2007-05-11 2016-08-23 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance
CN101607995B (zh) 2007-06-15 2013-05-01 厦门大学 特异性结合h5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途
AU2008297594B2 (en) 2007-09-13 2013-06-20 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
JP5490695B2 (ja) 2007-09-13 2014-05-14 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド インフルエンザウイルスｈ５亜型からのヘマグルチニンに特異的なモノクローナル抗体およびそれらの使用
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
MX2010006148A (es) 2007-12-06 2011-02-23 Dana Farber Cancer Inst Inc Anti-cuerpos contra el virus de la influenza y metodos de uso de los mismos.
AU2008349862B2 (en) 2008-02-05 2014-02-06 Temasek Life Sciences Laboratory Limited Binding protein and epitope-blocking ELISA for the universal detection of H5-subtype influenza viruses
US8669046B2 (en) 2008-03-12 2014-03-11 Xuguang (Sean) Li Reagents and methods for detecting influenza virus proteins
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
CN101990575B (zh) 2008-03-28 2015-06-17 国立大学法人北海道大学 抗h5亚型a型流感病毒血凝素单克隆抗体
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
ES2662519T3 (es) * 2008-07-25 2018-04-06 Institute For Research In Biomedicine Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
CA2736799A1 (en) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
CN102292350A (zh) 2008-12-24 2011-12-21 淡马锡生命科学研究院有限公司 对来自甲型流感病毒血凝素的融合肽特异的单克隆抗体及其用途
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
US8894997B2 (en) 2009-04-30 2014-11-25 Vanderbilt University Monoclonal antibodies to influenza H1N1 virus uses thereof
WO2010130636A1 (en) 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
WO2011019932A2 (en) 2009-08-14 2011-02-17 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9573991B2 (en) 2010-03-08 2017-02-21 Celltrion, Inc. Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
HRP20170490T1 (hr) 2010-03-26 2017-06-02 Pomona Ricerca S.R.L. Imunoglobulini pune dužine igg izotipa sposobni za prepoznavanje heterosubtipnog epitopa neutralizacije na području stabljike hemaglutinina i njihova uporaba kao lijek protiv gripe
JP6050747B2 (ja) * 2010-06-17 2016-12-21 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザ受動免疫化に有用な抗体
US8900590B2 (en) 2010-08-12 2014-12-02 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
SG187769A1 (en) 2010-08-23 2013-03-28 Temasek Life Sciences Lab Ltd Monoclonal antibody specific to major neutralizing epitope of influenza h5 hemagglutinin
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012045001A2 (en) 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
WO2012054745A1 (en) 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
CA2827301A1 (en) 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US8961978B2 (en) 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
CA2841551C (en) * 2011-07-18 2020-07-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
KR102050615B1 (ko) 2012-03-08 2019-11-29 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 b 바이러스들에 결합하고 중화할 수 있는 인간 결합 분자 및 그 용도
WO2013169377A1 (en) 2012-05-10 2013-11-14 Massachusetts Institute Of Technology Agents for influenza neutralization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US20140086927A1 (en) 2012-09-25 2014-03-27 Fujita Health University Novel epitope and mechanism of antigen-antibody interaction in an influenza virus
AU2013345072B2 (en) 2012-11-13 2017-12-07 Genentech, Inc. Anti-hemagglutinin antibodies and methods of use
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
JP6535675B2 (ja) 2013-10-02 2019-06-26 メディミューン，エルエルシー 抗ａ型インフルエンザ抗体の中和及びその使用
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
SMT202100307T1 (it) * 2018-01-26 2021-07-12 Regeneron Pharma Anticorpi e frammenti di legame di anti-tmprss2

Also Published As

Publication number Publication date
WO2016100807A3 (en) 2016-08-04
SG11201704212SA (en) 2017-06-29
MX386403B (es) 2025-03-04
EP3233908A2 (en) 2017-10-25
JP6711828B2 (ja) 2020-06-17
AU2015364415B2 (en) 2021-09-02
US10689436B2 (en) 2020-06-23
CL2019002196A1 (es) 2019-12-13
TW201632548A (zh) 2016-09-16
TWI702229B (zh) 2020-08-21
SG10202010170SA (en) 2020-11-27
JP2018503361A (ja) 2018-02-08
UY36458A (es) 2016-07-29
CN108064240A (zh) 2018-05-22
CO2017006580A2 (es) 2017-09-29
US11453714B2 (en) 2022-09-27
CL2017001610A1 (es) 2018-03-09
KR102729973B1 (ko) 2024-11-14
US20160176953A1 (en) 2016-06-23
EA201791086A1 (ru) 2018-01-31
BR112017012944A2 (pt) 2018-05-15
US20200377575A1 (en) 2020-12-03
EA036953B1 (ru) 2021-01-19
TW202026310A (zh) 2020-07-16
MY185320A (en) 2021-05-04
JP2019055996A (ja) 2019-04-11
PH12017500949A1 (en) 2017-10-02
AU2015364415A1 (en) 2017-06-15
US10392432B2 (en) 2019-08-27
TWI701258B (zh) 2020-08-11
IL252659A0 (en) 2017-07-31
KR20170098888A (ko) 2017-08-30
CN108064240B (zh) 2022-01-04
IL252659B (en) 2021-06-30
US20200017576A1 (en) 2020-01-16
CA2969749A1 (en) 2016-06-23
MX2021007679A (es) 2021-08-05
WO2016100807A2 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
CL2022003763A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
CO2019000968A2 (es) Anticuerpos anti-virus del zika y métodos de uso
MX2018007288A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
MX2016016533A (es) Combinaciones inmunogenas.
MX2015016627A (es) Vacuna para la malaria.
CL2020001884A1 (es) Anticuerpos humanos para la hemaglutinina de influenza.
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
CR20170518A (es) Neutralización del virus chikungunya mediada por anticuerpos.
MX392761B (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
UY37449A (es) Anticuerpos anti-chikv y usos de éstos
BR112017003332A2 (pt) uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica
CO2022005281A2 (es) Anticuerpos antihemaglutinina y métodos de uso de estos
HK1238655A1 (en) Human antibodies to influenza hemagglutinin
AR104480A1 (es) Anticuerpos humanos contra la glicoproteína del virus del ébola
EA202191973A2 (ru) Человеческие антитела к гликопротеину вируса эбола
AR095869A1 (es) Anticuerpos humanos que se unen a la proteína g del rsv